Setting up an R&D business in 2026 is generally considered to be a good idea. Venture capital money is flowing, and there are all sorts of new technologies coming onto the market across sectors and verticals, including energy, biotech, computing hardware, AI infrastructure, and more.

The key guiding principle behind this guide is to say to you that you shouldn’t chase hype. Instead, you should think about what type of research you’re doing from a first principles perspective, both physically, scientifically, and economically. 

Core guiding principles for R&D firms

You’ll want to start by considering your core guiding principles as an R&D firm. Before setting up your R&D startup, you should ask yourself:

• Whether it is following core guiding principles to the research and development sector.
• You’ll need to ask whether your research is something that is genuinely a bottleneck. If it’s not a bottleneck, then the payoff can be pretty low. For example, AI training is marginal right now, whereas 10 years ago, a lot of companies had leverage.
• You want to think about the magnitude of the improvement that your R&D could lead to. Usually, you want a 10x improvement far more than simply incremental gains, although it does depend on the industry.
• In addition to this, you’ll want to consider the timeline. Most R&D drives last between 3-7 years. If you think yours is going to be longer than this, then you’ll have to have a difficult conversation with your investors.
• Also, you should consider whether the development is feasible. If something is going to take longer than 7 years, it often means that it’s not possible with existing technology and approaches.

Research priorities in 2026

So, what are your actual research priorities in 2026? Where are you going to earn a return for all of your hard work? The most obvious area right now is AI efficiency and next-generation compute. Frontier AI models are energy-intensive and require giant data centers, often needing entire power plants of their own to run them. This is highly capital-intensive and not particularly sustainable, especially since the AI industry lacks customers right now. 

Research currently is looking into things like neuromorphic computing. The idea here is to give AI systems some of the efficiency of the brain. R&D start-ups are looking into software-hardware co-design for AI-native platforms, meaning that they are preemptively building chips that can cater to AI workloads. 

Biotech, weight loss drugs and peptides are another hot area right now. Many R&D firms are looking at ways that they can reduce the burden of disease and improve health technology across the board. With ageing populations, the requirements for personalised medicine and bio manufacturing are increasing, gene editing technologies are also opening up new doors and allowing researchers to perform interventions that would have been impossible just ten years ago. 

There are even AI-driven drug discovery platforms now coming to fruition. These are able to manipulate proteins and other molecules to indicate the best candidate drugs from a wide domain.